SCHEMBL5459036

SCHEMBL5459036

O=C(Nc1ccc(N2CCNCC2)c(Cl)c1)Nc1ccccc1F

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.57
NPC1 O15118 10/20 0.57
SMN1; SMN2 Q16637 6/20 0.57
GAA P10253 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
ALDH1A1 P00352 4/20 0.53
HPGD P15428 1/20 0.53
MAPT P10636 7/20 0.51
LMNA P02545 5/20 0.51
HTT P42858 5/20 0.50
PKM P14618 1/20 0.50
POLB P06746 1/20 0.50
MEN1 O00255 7/20 0.49
KMT2A Q03164 7/20 0.49
KDM4E B2RXH2 2/20 0.48
NPY2R P49146 2/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5467434 0.91 GAA (0.55) RAB9ANPC1SMN1; SMN2GAANPSR1
SCHEMBL5453449 0.85 NPC1 (0.56) RAB9ANPC1SMN1; SMN2GAANPSR1
SCHEMBL5458175 0.84 S1PR1 (0.58) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL5465662 0.82 NPC1 (0.59) RAB9ANPC1SMN1; SMN2GAANPSR1
SCHEMBL5465646 0.80 NPY2R (0.57) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL5464797 0.78 MEN1 (0.65) RAB9ANPC1SMN1; SMN2GAANPSR1
SCHEMBL5451242 0.77 NPC1 (0.53) RAB9ANPC1SMN1; SMN2GAANPSR1
SCHEMBL15818617 0.76 KDM4E (0.56) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL5470991 0.76 GAA (0.54) RAB9ANPC1SMN1; SMN2GAANPSR1
SCHEMBL5473571 0.75 TRPV1 (0.49) RAB9ANPC1SMN1; SMN2NPSR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 RAB9A 1528/4885NPC1 1089/4885SMN1; SMN2 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.